CNTXHealthcare · BiotechnologyThe 10 Wall Street analysts covering Context Therapeutics, Inc. hold a median 12-month price target of $4.5 — +1771.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Context Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CNTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1771.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 June 2026 | Maxim Group | Maintains | Buy | $8.00 → $4.00 |
| 16 June 2026 | Maxim Group | Maintains | Buy | — |
| 24 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 24 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 22 Dec 2025 | Jones Trading | Initiates | Buy | — |
| 6 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 Oct 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 7 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 June 2025 | Piper Sandler | Reiterates | Overweight | — |
| 8 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2025 | William Blair | Initiates | Outperform | — |
| 9 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Context Therapeutics, Inc. returned −82.1% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 78% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Context Therapeutics, Inc. has a market value of $23.5M and an enterprise value of −$19.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$46.0M.
Free cash flow in the twelve months to 30 June 2026: −$40.5M.
Trailing P/E: −0.7×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Context Therapeutics, Inc. employs 15 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Context Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research added Context Therapeutics (CNTX) to its Zacks Rank #5 (Strong Sell) List on October 15, 2026, alongside CDZI and CNSY.
Why it matters — CNTX watchers may note the stock's inclusion in Zacks' Strong Sell list.
Zacks Investment Research added Context Therapeutics (CNTX), along with ATS and CANG, to its Zacks Rank #5 (Strong Sell) list on October 13, 2026.
Why it matters — CNTX watchers may note the stock’s inclusion in Zacks’ Strong Sell list.
Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody being evaluated as a monotherapy in patients with urothelial, colorectal, and triple-negative breast cancers.
Why it matters — This milestone advances Context's lead TCE bispecific antibody program toward clinical data, marking progress in its pipeline for solid tumors.
Context Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided a pipeline update, including the prioritization of its CTIM-76 and CT-202 clinical programs with initial clinical readouts expected beginning in Q2 2027. The company also highlighted interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer receiving weekly dosing, and reported $43.0 million in cash and cash equivalents as of June 30, 2026, expected to fund operations into Q4 2027.
Why it matters — A CNTX watcher would track this update for the company's program prioritization, upcoming clinical readouts, and its cash runway extending into Q4 2027, which bears on how the pipeline can be advanced.
The 10 Wall Street analysts covering Context Therapeutics, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Context Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Context Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Context Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +1771.1% from the last close, and Ticker Nerd's factor model ranks Context Therapeutics, Inc. 28 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Context Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
Context Therapeutics, Inc. returned -82.1% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "New Strong Sell Stocks for October 15th". Zacks Investment Research added Context Therapeutics (CNTX) to its Zacks Rank #5 (Strong Sell) List on October 15, 2026, alongside CDZI and CNSY.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4. The company is advancing these candidates through early-stage clinical and preclinical development, with particular attention to cancers such as ovarian, endometrial, and breast cancer. Context Therapeutics Inc. operates as an oncology-focused biotechnology company and works to translate targeted immunotherapy research into potential treatments for genetically and biologically defined patient populations. Headquartered in Philadelphia, Pennsylvania, it remains centered on drug discovery and clinical development rather than commercialized products.
CEO Mr. Martin A. Lehr · 15 employees · United States · https://www.contexttherapeutics.com
